Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study

BackgroundPatients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is limited.MethodsThe Hokusai VTE Cancer trial compared edoxaban with dalteparin for VTE treatment in patients with active cancer. This post hoc analysis focused on the follow‐up period from 6 to...